Implementing Evidence-Based Guidelines for Hepatic Encephalopathy Management

Author(s):

Arun Jesudian, MD,Ralph J. Riello, PharmD, BCPS

Panelists explore the critical roles of lactulose and rifaximin in managing hepatic encephalopathy, a potentially severe condition that can lead to intensive care unit (ICU) admission.

EP: 1.Identifying and Screening for Hepatic Encephalopathy Risk Factors

EP: 2.Achieving Post-Discharge Success: Goals in Hepatic Encephalopathy Care

Now Viewing

Implementing Evidence-Based Guidelines for Hepatic Encephalopathy Management

EP: 1.Identifying and Screening for Hepatic Encephalopathy Risk Factors

EP: 2.Achieving Post-Discharge Success: Goals in Hepatic Encephalopathy Care

EP: 3.Implementing Evidence-Based Guidelines for Hepatic Encephalopathy Management

EP: 4.Addressing the Caregiver Burden in Hepatic Encephalopathy Management

EP: 5.Optimizing Care for Newly Diagnosed Hepatic Encephalopathy

EP: 6.Enhancing Hepatic Encephalopathy Care through Pharmacist-Prescriber Collaboration

EP: 7.Managing Adverse Events Associated with HE Therapies

EP: 8.Integrating Treatment Protocols and Community Pharmacy in HE Management

EP: 9.Promoting Adherence: Strategies for Maintaining HE Therapy

EP: 10.Empowering Pharmacists: Essential Insights for HE Management

EP: 11.Optimizing Transitions of Care for Hepatic Encephalopathy Patients

EP: 12.Collaborative Care: Key Stakeholders in HE Treatment and Recovery

EP: 13.Hepatic Encephalopathy: Critical Insights and Closing Thoughts